NeoMatriX Wound Matrix— 510(k) K210024

Name: FDA 510(k) clearance K210024
Creator: U.S. Food and Drug Administration
Published: 2021-10-07

Substantially Equivalent

Nextgen Biologics, Inc.

FDA 510(k) clearance K210024 for NeoMatriX Wound Matrix, Substantially Equivalent on 2021-10-07. Applicant: Nextgen Biologics, Inc.. Device class: Unclassified.

Clearance details

Applicant: Nextgen Biologics, Inc.
Product code: Code KGN
Device class: Unclassified
Advisory panel: Unknown
Date received: 2021-01-04
Decision date: 2021-10-07
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Alachua, FL, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code KGN

view all

K260652 — ColActive Plus2026-09-09
K260711 — Accelagen Plus Surgical Matrix, 1cc (CG-01AP) +4 more2026-08-27
K260596 — Collagen Wound Powder2026-07-02
K260669 — Endoform Dermal Template2026-06-24
K253521 — ECMT-100 WMD2026-06-18

More clearances from Nextgen Biologics, Inc.

view all

K181330 — NeoMatriX Wound Matrix2018-10-11

Adverse events under product code KGN

product code KGN

Other: 2
Total: 2

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.